國家衛生研究院 NHRI:Item 3990099045/15995
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 906563      Online Users : 958
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/15995


    Title: Discovery of a mu-opioid receptor modulator that in combination with morphinan antagonists induces analgesia
    Authors: Huang, YH;Lin, SY;Ou, LC;Huang, WC;Chao, PK;Chang, YC;Chang, HF;Lee, PT;Yeh, TK;Kuo, YH;Tien, YW;Xi, JH;Tao, PL;Chen, PY;Chuang, JY;Shih, C;Chen, CT;Tung, CW;Loh, HH;Ueng, SH;Yeh, SH
    Contributors: Institute of Biotechnology and Pharmaceutical Research;Center for Neuropsychiatric Research;NHRI Graduate Student Program
    Abstract: Morphinan antagonists, which block opioid effects at mu-opioid receptors, have been studied for their analgesic potential. Previous studies have suggested that these antagonists elicit analgesia with fewer adverse effects in the presence of the mutant mu-opioid receptor (MOR; S196A). However, introducing a mutant receptor for medical applications represents significant challenges. We hypothesize that binding a chemical compound to the MOR may elicit a comparable effect to the S196A mutation. Through high-throughput screening and structure-activity relationship studies, we identified a modulator, 4-(2-(4-fluorophenyl)-4-oxothiazolidin-3-yl)-3-methylbenzoic acid (BPRMU191), which confers agonistic properties to small-molecule morphinan antagonists, which induce G protein-dependent MOR activation. Co-application of BPRMU191 and morphinan antagonists resulted in MOR-dependent analgesia with diminished side effects, including gastrointestinal dysfunction, antinociceptive tolerance, and physical and psychological dependence. Combining BPRMU191 and morphinan antagonists could serve as a potential therapeutic strategy for severe pain with reduced adverse effects and provide an avenue for studying G protein-coupled receptor modulation.
    Date: 2024-07-17
    Relation: Cell Chemical Biology. 2024 Jul 17;Article in Press.
    Link to: http://dx.doi.org/10.1016/j.chembiol.2024.06.013
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2451-9448&DestApp=IC2JCR
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85200421803
    Appears in Collections:[Shiu-Hwa Yeh] Periodical Articles
    [Shau-Hua Ueng] Periodical Articles
    [Chun-Wei Tung] Periodical Articles
    [Chiung-Tong Chen] Periodical Articles
    [Chuan Shih(2014-2017)] Periodical Articles
    [Teng-Kuang Yeh] Periodical Articles
    [Pao-Luh Tao] Periodical Articles
    [Others] Periodical Articles
    [Shu-Yu Lin] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB39025070.pdf5908KbAdobe PDF41View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback